Cancer Research

Avery Posey’s cancer research takes high risks for big rewards

The assistant professor of systems pharmacology and translational therapeutics, who studied with Carl June as a postdoctoral fellow, combines his two research passions—gene therapy and investigating ‘little known’ biology—in the pursuit of new knowledge.

From Penn Medicine News

Blood test may help doctors catch pancreatic cancer early

A blood test may be able to detect the most common form of pancreatic cancer while it is still in its early stages while also helping doctors accurately stage a patient’s disease and guide them to the appropriate treatment.

John Infanti



Media Contact


Experts



In the News


The Washington Post

For those at risk for cancer, weighing the risk of COVID-19 with delays in screening and treatment

Lawrence Shulman of the Perelman School of Medicine says declining numbers of new cancer diagnoses over the past four months don’t mean fewer people actually have cancer. “There are a lot of patients out there who have cancer but are not undergoing diagnosis and entry into the cancer care system,” he said.

FULL STORY →



New Scientist

CRISPR cancer trial finds that gene-edited immune cells are safe

Edward Stadtmauer and Carl June of the Perelman School of Medicine spoke about a clinical trial that found it safe to inject CRISPR gene-edited immune cells into people with advanced cancer.

FULL STORY →



Science

Deciphering a cancer treatment’s dark side

Saar Gill of the Perelman School of Medicine said it would be easier to treat cancer using CAR-T cell therapy without the looming possibility of triggering cytokine release syndrome.

FULL STORY →



Scientific American

Could immunotherapy treat diseases besides cancer?

Jonathan Epstein of the Perelman School of Medicine is quoted on how immunotherapy has transformed cancer care.

FULL STORY →



Philadelphia Inquirer

The world’s first T-cell therapy for a solid tumor cancer is made in Philly

Carl June of the Perelman School of Medicine commented on news of Iovance Biotherapeutics’ new facilities in South Philadelphia. “Recent advances in the understanding of cancer and the immune system have made a compelling case that [tumor-infiltrating lymphocyte] therapy could be effective in diverse cancers beyond melanoma, such as lung cancer and cervical cancer,” he said. “The decision of Iovance to conduct commercial scale manufacturing in the Philadelphia Navy Yard is wonderful news.”

FULL STORY →



U.S. News & World Report

Fertility after cancer

Christos Coutifaris and Clarisa Gracia of the Perelman School of Medicine spoke about patients’ fertility options after cancer treatment.

FULL STORY →